C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC) Revenue
Annual & quarterly revenue history · segment & region breakdown
CCCC · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsC4 Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.03B, an increase of 1.02% year-over-year from $0.04B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.04B | +$0.00B | +1.02% |
| 2024-12-31 | $0.04B | +$0.01B | +71.44% |
| 2023-12-31 | $0.02B | -$0.01B | -33.25% |
| 2022-12-31 | $0.03B | -$0.01B | -32.08% |
| 2021-12-31 | $0.05B | +$0.01B | +37.93% |
| 2020-12-31 | $0.03B | +$0.01B | +55.25% |
| 2019-12-31 | $0.02B | +$0.00B | +10.42% |
| 2018-12-31 | $0.02B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income C4 Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
C4 Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from C4 Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CCCC revenue · 4 questionsCCCC's trailing twelve-month (TTM) revenue is $0.03B. That is an increase of 1.02% year-over-year from $0.04B in FY2025.
▸ Source: FMP · C4 Therapeutics, Inc. SEC filings · GAAP · C4 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026